Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Avidity Biosciences share holder equity from 2019 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Avidity Biosciences Share Holder Equity 2019-2025 | RNA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Avidity Biosciences share holder equity from 2019 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$209.6B
Amgen (AMGN)	$149.1B
Gilead Sciences (GILD)	$130.2B
Vertex Pharmaceuticals (VRTX)	$125.6B
Bristol Myers Squibb (BMY)	$100.2B
CSL (CSLLY)	$74.3B
GSK (GSK)	$74.1B
Regeneron Pharmaceuticals (REGN)	$61.6B
Argenex SE (ARGX)	$36.2B
Alnylam Pharmaceuticals (ALNY)	$30.5B
BioNTech SE (BNTX)	$23.7B
BeiGene (ONC)	$22.8B
Biogen (BIIB)	$17.4B
Genmab (GMAB)	$13.3B
Genmab (GNMSF)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.3B
Illumina (ILMN)	$11.3B
Incyte (INCY)	$11.3B
Ascendis Pharma (ASND)	$10.1B
Exelixis (EXEL)	$10B
Swedish Orphan Biovitrum (BIOVF)	$9.6B
Moderna (MRNA)	$9.6B
QIAGEN (QGEN)	$9B
Exact Sciences (EXAS)	$7.7B
Bio-Techne Corp (TECH)	$7.6B
Repligen (RGEN)	$7.3B
Halozyme Therapeutics (HALO)	$7.3B
Roivant Sciences (ROIV)	$7.2B
Revolution Medicines (RVMD)	$6.8B